Meet our partners

Six research centres and one pharmaceutical company fighting against WNV

Spain

IrsiCaixa was created as a private non-profit foundation in 1995. More than 30 years later, with a substantial accumulation of knowledge, IrsiCaixa has emerged as a leading force in the field of infection and immunity. While maintaining a steadfast commitment for eradicating HIV, over 200 committed researchers at IrsiCaixa apply their expertise to investigate other clinically significant viral, bacterial, and fungal infections. Examples include COVID-19, West Nile virus, syphilis, Ebola, respiratory syncytial virus, and multidrug-resistant bacteria. Furthermore, IrsiCaixa applies its understanding of the role of microorganisms and the resulting immune disorders to address medical challenges such as cancer, Alzheimer, aging, and the microbiome. 

Two groups of Barcelona Supercomputing Center will participate in the project:

  • The Computational Biology group has years of experience conducting protein studies based on their sequences and structures. It also has broad expertise in the application of ML and AI techniques in the field of structural bioinformatics and protein interactions.
  • The Electronic and Atomic Protein Modeling group has profound experience in protein engineering and stabilisation. They have also developed state of-the-art tools in immunoinformatics and vaccine design. The combined know-how of these leading academia groups will serve as a basis for the successful in silico design of the immunogen candidates.

The Centre for Genomic Regulation is a research institute with scientists from more than 40 countries. It is the first Spanish research centre and the third Spanish entity in H2020- SC1-Health, and it manages 71 projects in FP7, and approximately 100 projects in H2020. The Protein Technologies Unit (PTU) provides the researchers at the CRG-CNAG/PRBB, external institutions and private companies with a new, high quality technology platform to perform protein production and characterization and automated processes in the context of biomolecular and biochemical screening assays.

HIPRA is a biotechnological pharmaceutical company focused on prevention for animal and human health, with a broad range of highly innovative vaccines. It has a wide experience in working with 300 different pathogens. So, it is very aware of the pathologies that could also affect humans as their etiologic agents are zoonotic. In the animal health area, HIPRA develops vaccines for both livestock-and-companion animals. Moreover, HIPRA has recently achieved registering the BIMERVAX® vaccine in the EMA, a vaccine intended to protect humans against the SARS-CoV-2 virus causing COVID-19. This demonstrates its experience in developing and registering vaccines for human health. 

France

Université de Montpellier is a research-intensive university where education and research cover most of the Scientific and Technological fields. Research at UM is structured into 74 laboratories most of which are in partnership with well-recognized French research organizations such as CNRS, INSERM, IRD, INRA or CIRAD. UM also comprises 16 technology platforms and services centres offering access to the state-of the-art research facilities for its researchers and research groups.

Germany

The Technische Universität Braunschweig was founded in 1745 and is the oldest university of technology in Germany. The university is member of “TU9 German Universities of Technology”, an alliance of the leading German universities of technologies.

Denmark

The Kloverpris lab has vast experience in studying immune response to viral infections in human blood and tissue. A key aspect of this work is their human tonsil organoid model, based on already approved ethical protocols, that they will utilise to study the immune response to viral and vaccine candidates relevant to a human in vivo setting. 

Researchers

IrsiCaixa

Jorge Carrillo

Coordinator of the project

IrsiCaixa – WP5 & WP6 Leader

Julia G. Prado

IrsiCaixa- WP4 Leader

Julià Blanco

IrsiCaixa – WP3 & WP4

Nuria Izquierdo

IrsiCaixa – WP4

Laia Vives

IrsiCaixa- WP9

Eudald Vehí

IrsiCaixa – WP4

María Lázaro

IrsiCaixa – WP4

Raúl Pérez

IrsiCaixa – WP4

Mª Luisa Rodríguez

IrsiCaixa- WP5 & WP6

Dàlia Raïch

IrsiCaixa – WP4

Eloi Franco

IrsiCaixa – WP4

Francesc Cunyat

IrsiCaixa – WP3 & WP4

Nuria Pedreño

IrsiCaixa – WP5 & WP6

Marina Matilla

IrsiCaixa – WP5 & WP6

Rosina Malagrida

IrsiCaixa – WP9

Barcelona Supercomputing Center

Alfonso Valencia

BSC – WP1

Camila Pontes

BSC – WP1

Miguel Romero

BSC – WP1

Roc Farriol

BSC – WP1

Victor Guallar

BSC – WP1

Victor Montal

BSC – WP1

Institute for Regenerative Medicine and Biotherapy (University of Montpellier)

Mar Naranjo Gómez

IRMB – WP5 & WP7

Mireia Pelegrin

IRMB – WP5 & WP7

Pathogenesis and Control of Chronic and Emerging Infections (University of Montpellier)

Yannick Simonin

PCCEI – WP5 & WP7

HIPRA

Laura Ferrer

HIPRA – WP5, WP8 & WP9

Teresa Prat

HIPRA – WP8

Centre for Genomic Regulation (CRG)

Carlo Carolis

CRG – WP2, WP8 & WP9

Natalia Rodrigo

CRG – WP2, WP8 & WP9

Katie Broadbent

CRG – WP2, WP8 & WP9

Isabel Latorre

CRG – WP2, WP8 & WP9

Mar López

CRG – WP2